Navigation Links
Intarcia Therapeutics Announces Presentation of Final Results From,a Phase 2 Combination Study for the Treatment of Hepatitis C at the,Digestive Disease Week Conference

Potent synergy, activity and patient tolerance observed in Genotype 1 patients support development of Omega DUROS(R) continuous delivery therapy

WASHINGTON, May 21, 2007 /PRNewswire/ -- Intarcia Therapeutics, Inc., a privately held biopharmaceutical company, today announced the presentation of final results from a Phase 2 study comparing the combination of injectable omega interferon and ribavirin to omega interferon alone in treatment-naive patients with genotype 1 chronic hepatitis C. The results demonstrate that omega interferon in combination with ribavirin is well tolerated and shows robust antiviral activity that is comparable to published data on the use of alpha interferon plus ribavirin in similar patient populations. The 72-week sustained viral response (SVR) data are being presented today at the Digestive Disease Week Conference in Washington, DC by Bruce R. Bacon, MD, Professor of Internal Medicine, Saint Louis University Medical Center, St. Louis, Missouri.

This Phase 2 study of daily subcutaneous omega interferon injections provides Intarcia with safety and clinical response data to support development of omega interferon delivered by continuous release from the DUROS(R) device.

"The safety and SVR rates achieved in this phase 2 study are encouraging in that they indicate that the combination of omega interferon and ribavirin may produce response rates which are similar to those achieved with alpha interferon and ribavirin in patients with HCV genotype-1," said Dr. Bacon. "The positive results of this study allow us to proceed with the evaluation of continuous delivery of omega interferon delivered with the DUROS device. A trial evaluating dose response of the Omega DUROS device is expected to begin in the near future."

The Phase 2 trial compared the safety and antiviral response of omega interferon alone with omega interferon in combination with ribavirin in 102 interferon-na
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Intarcia Therapeutics Announces Final Results From a Phase 2 Study of Injectable Omega Interferon plus Ribavirin for the Treatment of Hepatitis C Genotype-1
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
10. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
11. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
Post Your Comments:
(Date:5/15/2008)...BRIDGEWATER, N.J., May 15 /...ounced today that findings from the,landmark ATHEN...l therapy,for the treatment of patients with atria...sk of cardiovascular hospitalizations or death fro...0.00000002), meeting the study,primary endpoint. T...
(Date:5/15/2008)...BOSTON, May 15 /- CenterWatch, a publ... market research about clinical,trials, finds that...e EDC,(electronic data capture) systems. More than... indicated that they had been trained on three or ...d that the effectiveness of,their EDC training had...
(Date:5/15/2008)...care Advantage Fee-For-Service Plan Positions Blue...iness, According to a New Report from ...enn., May 15 /- HealthLeaders-InterSt...ntelligence, reports that as the,economy continues...f,Michigan remains the best equipped of all of its...
(Date:5/15/2008)...GREEN BAY, Wis., May 15 /- Omega 3 fa...rther considered as a credible natural,alternative...ADHD patients,recent in vivo French study reveals...ffects of omega-3 in hyperactivity, French researc...e specific positive effects on,impulse control., ...
Breaking Medicine Technology:Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 2Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 3Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 4Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 5Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 6Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 7CenterWatch Releases State of the Clinical Trials Industry 2008 - A Key Industry Resource for Market Research and Competitive Intelligence 2Blue Cross Blue Shield Of Michigan Battles Sluggish Economy With Diverse Product Lineup 2Omega 3 Fatty Acids Bound to Phospholipids has Potential Benefit for Attention-Deficit Hyperactivity Disorder (ADHD) 2Omega 3 Fatty Acids Bound to Phospholipids has Potential Benefit for Attention-Deficit Hyperactivity Disorder (ADHD) 3Congenital heart defects increasing among IVF twins 10631 1Congenital heart defects increasing among IVF twins 10631 2Max Nutrition Inc Completes Share Exchange with American Spring Pharmaceutical Inc 2906 1Max Nutrition Inc Completes Share Exchange with American Spring Pharmaceutical Inc 2906 2Pennsylvania Governor Rendell Announces 241 8 Million Investment to Add Nurses Improve Nurse Education Grants Awarded to Recipients in 28 Counties 10627 1Pennsylvania Governor Rendell Announces 241 8 Million Investment to Add Nurses Improve Nurse Education Grants Awarded to Recipients in 28 Counties 10627 2Pennsylvania Governor Rendell Announces 241 8 Million Investment to Add Nurses Improve Nurse Education Grants Awarded to Recipients in 28 Counties 10627 3Pennsylvania Governor Rendell Announces 241 8 Million Investment to Add Nurses Improve Nurse Education Grants Awarded to Recipients in 28 Counties 10627 4Halogen Advances its Lead in Providing Employee Performance and Talent Management Solutions for the Healthcare Market 2904 1Halogen Advances its Lead in Providing Employee Performance and Talent Management Solutions for the Healthcare Market 2904 2
...INNEAPOLIS--(BUSINESS WIRE)--Mar 26, 2007 - Two-ye...III trial confirm the positive,clinical profile of...ring to nearly 1,300 the number of Endeavor patien...ficantly, among those 1,300,Endeavor patients, the...bosis using the independent, pre-specified clinica...
... Company Set to Host Evening Symposium at ATC -,...nced today that,an independent data monitoring c...data from the Phase 2b kidney transplant (PROMISE)...proximately 1/3 of,the anticipated 332 patients ... trial continue according to the original study,...
Other Medicine Technology:Two-Year Results from the Medtronic ENDEAVOR III Trial Confirm,Stent's Positive Clinical Profile 2Two-Year Results from the Medtronic ENDEAVOR III Trial Confirm,Stent's Positive Clinical Profile 3Isotechnika's independent data monitoring committee conducts review,of phase 2b kidney transplant trial 2Isotechnika's independent data monitoring committee conducts review,of phase 2b kidney transplant trial 3Isotechnika's independent data monitoring committee conducts review,of phase 2b kidney transplant trial 4
(Date:5/16/2008)...R, Minn., May 16 /PRNewswire-USNewswire/ -- This r...Mayo Clinic in conjunction with the,National Cance...udy being presented at the American Society of Cli..., may change treatment practice,in about 25 percen...or,proposed changes to the way colorectal cancers ...
(Date:5/16/2008)... Covers More than 500 Workers, WASHINGTON, May 16...cs,and emergency medical technicians in the Greate...have ratified their first-ever contract as,Teamste...s are now covered by a,strong contract that gives ...," said Teamsters General President Jim Hoffa., T...
(Date:5/16/2008)...rom an international, multicenter Phase III clinic...therapy everolimus (RAD001) significantly delays c...ey cancer whose disease had worsened on other trea...n attending physician at Memorial Sloan-Kettering ...gs on May 31 at the annual meeting of the American...
(Date:5/16/2008)...n) Declaring that Primary care medicine is in a p...dent of the American College of Physicians (ACP), ...oyers and consumers to issue a call for comprehens... internists and other primary care physicians. ,...y care medicine in the U.S., Dr. Dale and other pa...
Breaking Medicine News(10 mins):Health News:New Method Proposed for Determining Which Patients Should Get Treatment for Colorectal Cancer 2Health News:Drug fends off kidney cancer progression 2Health News:ACP says major system reforms needed to improve the state of primary care medicine in the US 2
...revent, a powdered medication inhaled by asthma pa...us of an FDA Pulmonary-Allergy Drugs Advisory Comm...aths related to asthmatic symptoms in patients who...FDA documents released yesterday indicate that abo...
...ase III clinical trial of Ruboxistaurin (RBX) at a... inhibit Protein kinase C (PKC) – beta inhibitor, ...ith diabetes. The study was conducted in 252 pat...the Research team of Joslin Diabetes Centre across...
...e incidence of asthma, hay fever or any of the all...f brain cancer that may be fatal. Variations in ce...ore prone to the attacks of asthma and other aller...ns also prevent the incidence of the most common f...
... interesting study done in Nepal and India has sho...stoves is associated with increased risk of develo...ct has been found to be widely prevalent in develo... present study examined the association between co...
Other Medicine News:
This handheld reference is a practical guide to established surgical oncology principles for each organ system.
The Editors and Contributors are a virtual "Who's Who" in surgery, and they have prepared an outstanding program that provides expert advice on a full range of problems. Destined to be the "gold stan
The First Aid for the Surgery Clerkship is designed to prepare for the surgery clerkship examination and provides clinical diagnosis and treatment of many of the problems seen by surgeons.
CURRENT Consult: Surgery brings you authoritative clinical answers on more than 360 surgically treated disorders in the most efficient format, perfectly devised for the busy physician.
Medicine Products: